Combination of vascular targeting PDT with combretastatin A4 phosphate

Chong He; Babasola Fateye; Bin Chen

doi:10.1117/12.822969

Translator Disclaimer

13 July 2009 Combination of vascular targeting PDT with combretastatin A4 phosphate

Chong He; Babasola Fateye; Bin Chen

Author Affiliations +

Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 738032 (2009) https://doi.org/10.1117/12.822969
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States

Abstract

Tumor vasculature is an attractive target for cancer therapy due to its accessibility to blood-borne therapeutic agents and the dependence of tumor cells on a functional blood supply for survival and growth. Vascular targeting photodynamic therapy (vPDT) is a novel modality based on the selective laser light activation of photosensitizers localized inside tumor vasculature to shutdown tumor vascular function. Although this vascular targeting therapy is showing great promise for cancer treatment, tumor recurrence has been observed in both preclinical and clinical studies. In this study, we intend to enhance the therapeutic outcome of vascular targeting PDT by combining it with combretastatin A4 phosphate (CA4P), a blood flow inhibitor. We found that the combination of CA4P and vPDT significantly increased endothelial cell apoptosis than each single therapy. Western blot analysis suggests that myosin light chain kinase (MLCK) is a common target of CA4P and vPDT. In a PC-3 prostate tumor model, we found that CA4P was able to greatly enhance tumor response to vPDT. These results demonstrate that CA4P and vPDT can be combined to enhance the therapeutic effect.

Citation Download Citation

Chong He, Babasola Fateye, and Bin Chen "Combination of vascular targeting PDT with combretastatin A4 phosphate", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 738032 (13 July 2009); https://doi.org/10.1117/12.822969

ACCESS THE FULL ARTICLE